1-20 of 90397
Sort by
Journal Article
ACCEPTED MANUSCRIPT
Haoling Chen and others
The Journal of Infectious Diseases, jiaf207, https://doi.org/10.1093/infdis/jiaf207
Published: 18 April 2025
Image
Published: 18 April 2025
Figure 2. ABL/PI5P-amikacin combined treatment reduces Mab285 intracellular viability in macrophages of PWCF who do not receive ETI therapeutic regimen. MDM from PWCF without a modulator regimen (n = 6) were cultured at a concentration of 1 × 10 6 cells/mL in 96-well plates. Cells were then infected with My
Journal Article
Tommaso Olimpieri and others
The Journal of Infectious Diseases, jiaf124, https://doi.org/10.1093/infdis/jiaf124
Published: 18 April 2025
Image
Published: 18 April 2025
Figure 1. ABL/PI5P reduces Mycobacterium abscessus intracellular viability in macrophages from PWCF irrespective of ETI therapeutic regimen eligibility. Monocyte-derived macrophages from PWCF under an ETI regimen (n = 15) ( A ) or from PWCF without a modulator regimen (n = 15) ( B ) were cultured at a conce
Journal Article
ACCEPTED MANUSCRIPT
So-young Lee and others
The Journal of Infectious Diseases, jiaf202, https://doi.org/10.1093/infdis/jiaf202
Published: 17 April 2025
Image
Published: 17 April 2025
Graphical Abstract Graphical Abstract
Journal Article
ACCEPTED MANUSCRIPT
Anne C Martin and others
The Journal of Infectious Diseases, jiaf188, https://doi.org/10.1093/infdis/jiaf188
Published: 17 April 2025
Journal Article
ACCEPTED MANUSCRIPT
E A Mackay and others
The Journal of Infectious Diseases, jiaf195, https://doi.org/10.1093/infdis/jiaf195
Published: 17 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Matthew A Beier and others
The Journal of Infectious Diseases, jiaf191, https://doi.org/10.1093/infdis/jiaf191
Published: 16 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Heekuk Park and others
The Journal of Infectious Diseases, jiaf194, https://doi.org/10.1093/infdis/jiaf194
Published: 16 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Yongsen Wang and others
The Journal of Infectious Diseases, jiaf192, https://doi.org/10.1093/infdis/jiaf192
Published: 16 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Kenyon Chris
The Journal of Infectious Diseases, jiaf199, https://doi.org/10.1093/infdis/jiaf199
Published: 16 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Juan Carlos Espinosa and others
The Journal of Infectious Diseases, jiaf170, https://doi.org/10.1093/infdis/jiaf170
Published: 15 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Dariya Nikitin and Peter J White
The Journal of Infectious Diseases, jiaf200, https://doi.org/10.1093/infdis/jiaf200
Published: 15 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Rui-Lin Yan and others
The Journal of Infectious Diseases, jiaf193, https://doi.org/10.1093/infdis/jiaf193
Published: 15 April 2025
Image
Published: 12 April 2025
Figure 3. Estimated number of influenza-associated hospitalizations averted in each initial testing and prescribing scenario as compared with a baseline scenario without antivirals. Antiviral effectiveness is fixed at its highest value (70% reduction in risk of hospitalization for early care seekers and 35% f
Journal Article
Sinead E Morris and others
The Journal of Infectious Diseases, jiaf061, https://doi.org/10.1093/infdis/jiaf061
Published: 12 April 2025
Image
Published: 12 April 2025
Figure 2. Simulated parameter inputs. Input parameter distributions were generated by taking 1000 samples from their corresponding probability distributions and are shown as violin plots. Risk stratifications refer to groups with high or low risk of influenza-associated hospitalization; full compliance refers
Image
Published: 12 April 2025
Figure 1. Model structure within each age group and risk stratification. The risk of hospitalization for individuals with symptomatic influenza infection depends on whether individuals seek care, the timing of care seeking, the occurrence and result of testing, the prescribing of antiviral treatment, and the
Image
Published: 12 April 2025
Figure 4. Estimated influenza-associated hospitalizations averted in select alternative scenarios as compared with a baseline scenario without antivirals. A , Number of hospitalizations averted. B , Percentage of hospitalizations averted. C , Number of prescriptions needed to avert 1 hospitalization. Scena